

October 6, 2017



## Molecular Templates to Present at the 2017 BIO Investor Forum

AUSTIN, Texas, Oct. 06, 2017 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in oncology, today announced that Eric E. Poma, Ph.D., Chief Executive and Chief Scientific Officer, will provide a corporate overview at the 2017 BIO Investor Forum, being held October 17-18 in San Francisco, California.

### ***BIO Investor Forum***

Date: Tuesday, October 17

Time: 10:30am Pacific Time

Location: Westin St. Francis, San Francisco, Elizabethan C Ballroom

Webcast: <http://www.veracast.com/webcasts/bio/investorforum2017/25111335172.cfm>

### **About Molecular Templates**

Molecular Templates is focused on the discovery, development and commercialization of next-generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancers and other serious diseases. For additional information, please visit Molecular Templates' website at [www.mtem.com](http://www.mtem.com).

### **Investor Contact:**

Andrew McDonald, Ph.D.  
[andrew@lifesciadvisors.com](mailto:andrew@lifesciadvisors.com)  
646-597-6987



Source: Molecular Templates